AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Last update at 2024-04-24T20:00:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -108.12200M | -57.94300M | -51.97200M | - |
| Minority interest | - | - | - | - |
| Net income | -108.17600M | -58.23500M | -51.86400M | - |
| Selling general administrative | 30.02M | 17.60M | 9.87M | - |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 24.86M | 37.04M | 7.66M | - |
| Reconciled depreciation | 1.61M | 0.90M | 0.72M | - |
| Ebit | -112.67900M | -59.08700M | -52.20000M | -15.16200M |
| Ebitda | -111.07100M | -58.19000M | -51.48200M | - |
| Depreciation and amortization | 1.61M | 0.90M | 0.72M | - |
| Non operating income net other | -1.44700M | -1.03000M | - | - |
| Operating income | -111.07100M | -58.19000M | -52.20000M | - |
| Other operating expenses | 135.93M | 95.23M | 59.86M | - |
| Interest expense | 2.95M | 1.14M | 0.00000M | 0.00000M |
| Tax provision | 0.05M | 0.29M | 0.00000M | - |
| Interest income | 1.46M | 0.49M | 0.11M | - |
| Net interest income | 1.46M | 0.49M | 0.11M | - |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | 0.05M | 0.29M | -0.10800M | - |
| Total revenue | 24.86M | 37.04M | 7.66M | - |
| Total operating expenses | 135.93M | 95.23M | 59.86M | - |
| Cost of revenue | - | - | - | - |
| Total other income expense net | 2.95M | 0.25M | 0.23M | - |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -108.17600M | -58.23500M | -51.97200M | - |
| Net income applicable to common shares | -108.17600M | -58.23500M | -51.97200M | -14.09500M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 436.47M | 500.15M | 207.25M | - |
| Intangible assets | - | - | - | - |
| Earning assets | - | - | - | - |
| Other current assets | 6.57M | 4.52M | 1.31M | - |
| Total liab | 186.99M | 155.41M | 168.65M | - |
| Total stockholder equity | 249.48M | 344.75M | 38.60M | - |
| Deferred long term liab | - | - | - | - |
| Other current liab | 17.53M | 9.94M | 6.14M | 19.93M |
| Common stock | 0.09M | 0.09M | 0.04M | 0.01M |
| Capital stock | 0.09M | 0.09M | 0.04M | - |
| Retained earnings | -269.51200M | -161.33600M | -103.10100M | -51.12900M |
| Other liab | - | 114.72M | 120.81M | 14.12M |
| Good will | - | - | - | - |
| Other assets | - | 1.73M | 166.82M | 2.28M |
| Cash | 59.97M | 142.75M | 28.38M | - |
| Cash and equivalents | - | - | - | - |
| Total current liabilities | 55.55M | 40.69M | 40.92M | 25.85M |
| Current deferred revenue | 31.79M | 26.02M | 31.98M | - |
| Net debt | -18.83700M | -141.24200M | -20.49700M | - |
| Short term debt | 1.77M | 1.50M | 0.96M | - |
| Short long term debt | - | - | - | - |
| Short long term debt total | 41.13M | 1.50M | 7.88M | - |
| Other stockholder equity | 522.61M | 506.76M | 141.64M | 0.01000M |
| Property plant equipment | 10.88M | 6.09M | 11.30M | 11.83M |
| Total current assets | 375.27M | 492.34M | 193.63M | 41.66M |
| Long term investments | - | - | - | - |
| Net tangible assets | 249.48M | 344.75M | -97.94400M | -47.79500M |
| Short term investments | 306.17M | 342.51M | 161.94M | - |
| Net receivables | 2.00M | 2.00M | 2.00M | - |
| Long term debt | - | - | - | - |
| Inventory | 0.57M | 0.57M | - | - |
| Accounts payable | 4.45M | 3.23M | 1.84M | 0.67M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | -3.70500M | -0.76500M | 0.02M | - |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | 0.09M | 0.09M | 157.36M | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | -269.51200M | -161.33600M | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | 3.43M | 1.73M | 2.32M | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 61.20M | 7.82M | 13.62M | - |
| Capital lease obligations | 41.13M | 1.50M | 7.88M | - |
| Long term debt total | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | 34.09M | -181.59700M | -144.32000M | 2.67M |
| Change to liabilities | -8.13400M | -10.81000M | 120.25M | -15.22500M |
| Total cashflows from investing activities | 26.40M | -183.43400M | -145.46600M | 0.85M |
| Net borrowings | - | - | - | - |
| Total cash from financing activities | 1.61M | 357.32M | 80.88M | 11.00M |
| Change to operating activities | - | -0.53500M | 0.42M | 1.70M |
| Net income | -108.17600M | -58.23500M | -51.97200M | -14.09500M |
| Change in cash | -81.06600M | 114.36M | 5.49M | -12.95500M |
| Begin period cash flow | 145.02M | 30.66M | 25.17M | - |
| End period cash flow | 63.96M | 145.02M | 30.66M | 25.17M |
| Total cash from operating activities | -109.08000M | -59.52700M | 70.07M | -24.80300M |
| Issuance of capital stock | 0.00000M | 29.99M | 80.84M | - |
| Depreciation | 1.61M | 0.90M | 0.72M | 0.64M |
| Other cashflows from investing activities | - | - | -0.04000M | -0.04000M |
| Dividends paid | - | - | - | - |
| Change to inventory | - | - | 0.42M | - |
| Change to account receivables | - | 0.00000M | -2.00000M | -2.00000M |
| Sale purchase of stock | - | 31.05M | - | - |
| Other cashflows from financing activities | -0.00800M | 327.33M | -145.46600M | 326.28M |
| Change to netincome | 13.56M | 9.16M | 2.65M | 2.18M |
| Capital expenditures | 7.69M | 1.84M | 1.11M | 1.82M |
| Change receivables | - | - | - | - |
| Cash flows other operating | -7.93900M | -3.29500M | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | -81.06600M | 114.36M | - | - |
| Change in working capital | -18.49300M | -11.34500M | 118.67M | - |
| Stock based compensation | 14.23M | 7.83M | 1.76M | - |
| Other non cash items | 1.75M | 1.32M | 0.89M | - |
| Free cash flow | -116.77200M | -61.36400M | 68.97M | - |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics Inc |
-0.01 0.13% | 7.76 | - | - | 26.76 | 3.62 | 18.16 | -6.3447 |
| NVO Novo Nordisk A/S |
-2.48 1.93% | 126.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.58 1.23% | 126.80 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.15 1.02% | 400.76 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-0.61 0.67% | 90.10 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
100 Binney Street, Cambridge, MA, United States, 02142
| Name | Title | Year Born |
|---|---|---|
| Dr. Barbara L. Weber M.D. | Pres, CEO & Director | 1956 |
| Ms. Daniella Beckman CPA | Chief Financial Officer | 1979 |
| Dr. Alan Huang Ph.D. | Chief Scientific Officer | 1973 |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | 1961 |
| Dr. Levi Garraway M.D., Ph.D. | Founder | NA |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | 1958 |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder | 1981 |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 1967 |
| Mr. Douglas J. Barry Esq., J.D. | Gen. Counsel, Chief Compliance Officer & Corp. Sec. | 1970 |
| Mr. John C. Ross M.S. | VP of HR | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...